TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $52.50.

A number of equities analysts have recently issued reports on TGTX shares. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of TG Therapeutics in a report on Wednesday, May 27th.

TG Therapeutics Price Performance

TGTX opened at $53.22 on Friday. The stock has a 50-day moving average price of $39.81 and a 200-day moving average price of $33.63. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $54.07. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $8.15 billion, a P/E ratio of 18.61 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The firm had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. TG Therapeutics’s revenue for the quarter was up 69.5% compared to the same quarter last year. Equities analysts predict that TG Therapeutics will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. First Nebraska Trust Co purchased a new position in shares of TG Therapeutics in the 1st quarter worth about $233,000. Bank of America Corp DE boosted its holdings in TG Therapeutics by 71.7% during the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after acquiring an additional 610,195 shares during the period. Edgestream Partners L.P. purchased a new stake in TG Therapeutics during the 1st quarter valued at about $5,593,000. Amundi purchased a new stake in TG Therapeutics during the 1st quarter valued at about $460,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 365 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.